CX-5461 potentiates imatinib-induced apoptosis in K562 cells by stimulating KIF1B expression (Part 4)

The selective RNA polymerase I inhibitor CX-5461 has been shown to be effective in treating some types of leukemic disorders. Emerging evidence suggests that combined treatments with CX-5461 and other chemotherapeutic agents may achieve enhanced effectiveness as compared to monotherapies. In the present study, we tested whether CX-5461 could potentiate the effect of imatinib in the human chronic myeloid leukemia cell line K562. Cells were divided into 3 treatment groups (with 3 independent biological replications in each group): control, imatinib (100 nM for 48 hr) alone, and imatinib+CX-5461 (100 nM for 48 hr). Genome-wide mRNA sequencing was performed.选择性RNA聚合酶I（RNA polymerase I）抑制剂CX-5461已被证实可有效治疗部分白血病类疾病。新近研究证据表明，相较于单药治疗，CX-5461与其他化疗药物联合使用可获得更强的治疗效能。本研究旨在探究CX-5461是否能够增强伊马替尼（imatinib）对人慢性髓系白血病细胞株K562的作用效果。实验中将细胞分为3个处理组（每组设置3次独立生物学重复）：对照组、单独伊马替尼处理组（100 nM浓度孵育48小时）以及伊马替尼联合CX-5461处理组（两种药物终浓度均为100 nM，孵育48小时）。随后对各组样本开展全基因组mRNA测序（genome-wide mRNA sequencing）分析。